This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ultragenyx Pharmaceutical Inc.
Drug Names(s): UX001, UX-001 sialic acid extended release (SA-ER), aceneuramic acid extended release
Description: UX001 is an extended release formulation of sialic acid that should allow themaintenance of steady levels of sialic acid after oral administration. The sialic acidreplacement therapy is expected to restore the proper biochemistry of glycoproteinsand glycolipids by allowing proper sialylation. Data from an HIBM (Hereditary Inclusion Body Myositis) mouse model show aprofound beneficial effect of sialic acid replacement therapy on the biochemistry,pathology and clinical outcomes of HIBM mice.
Pink Sheet US FDA, Advisory Committees Rarely Disagree
Additional information available to subscribers only: